<?xml version="1.0" encoding="UTF-8"?>
<notes>
 <fn-group>
  <fn fn-type="COI-statement">
   <p>
    <bold>Conflict of interest:</bold> AM, AT and LB are members of the Respiratory Syncytial Virus Consortium in Europe (RESCEU). RESCEU has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement 116019. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations. LB is member of the Respiratory Syncytial Virus Network (ReSViNET) and has regular interaction with pharmaceutical and other industrial partners. He has not received personal fees or other personal benefits. UMCU has received major funding (&gt; €100,000 per industrial partner) for investigator initiated studies from AbbVie, MedImmune, Janssen, the Bill and Melinda Gates Foundation and MeMed Diagnostics. UMCU has received minor funding participation in trials by Regeneron and Janssen since 2015 (total annual estimate less than €20,000). He received minor funding for consultation and invited lectures by AbbVie, MedImmune, Ablynx, Bavaria Nordic, MabXience, Novavax, Janssen (total annual estimate less than €20,000). All other authors declare no competing interests.
   </p>
  </fn>
  <fn fn-type="con">
   <p>
    <bold>Authors’ contributions:</bold> LV, AT and AM designed the study. AM and GD were responsible for the sentinel surveillance. LV carried out the analysis of the data jointly with AM, JL and TV. LV wrote the manuscript jointly with AM. AH, LB, JO provided input on the manuscript from a clinical point of view. All authors critically reviewed the manuscript and provided valuable comments.
   </p>
  </fn>
 </fn-group>
</notes>
